Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ID Biomedical To Initiate Fluviral Trial For U.S. Approval By End Of January

This article was originally published in The Pink Sheet Daily

Executive Summary

ID Biomedical will begin enrolling subjects in a clinical trial evaluating its influenza vaccine Fluviral for U.S. approval before the end of January

You may also be interested in...



FDA Accepts ID Biomedical’s Fluviral For Accelerated Approval Pathway

Accelerated approval could allow the company to market the influenza vaccine in the U.S. in time for the 2006-2007 flu season, the company says. ID Biomedical previously discussed the possibility of launching in 2005.

FDA Accepts ID Biomedical’s Fluviral For Accelerated Approval Pathway

Accelerated approval could allow the company to market the influenza vaccine in the U.S. in time for the 2006-2007 flu season, the company says. ID Biomedical previously discussed the possibility of launching in 2005.

FDA Using “Dual-Track” Plan To Strengthen 2005-2006 Flu Vaccine Supply

The agency will inspect Chiron’s Liverpool manufacturing facility in the spring to determine whether the company has “adequately addressed its problems,” CBER Director Goodman tells House committee. FDA informs manufacturers that it will allow accelerated approval of flu vaccines using surrogate endpoints.

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel